Type 2 diabetes causes a persons blood sugar level to become too high, and if blood sugar isnt controlled properly and stays too high, a number of problems can occur including kidney failure, nerve damage, heart disease and stroke.

So what can be done to prevent the condition and keep blood sugar levels in check?

Eating a healthy diet is just one of the ways blood sugar levels can be managed.

The NHS advises: "Theres nothing you cannot eat if you have type 2 diabetes, but youll have to limit certain foods.

You should eat a wide range of foods - including fruit, vegetables and some starchy foods like pasta, keep sugar, fat and salt to a minimum, and eat breakfast, lunch and dinner every day - do not skip meals.

READ MORE:How to get rid of visceral fat: The best drink to reduce the harmful belly fat

But when it comes to the first meal of the day, breakfast, one food that should be avoided is cereal bars.

Diabetes UK states: Cereal bars arent always as healthy as they appear.

For a better breakfast snack on the go, grab some fresh fruit and a handful of nuts instead.

Combine it with a glass of semi or skimmed milk to keep hydrated and get essential calcium for your bones and teeth.

DON'T MISS

Cereal can also hold a similar problem. The diabetes charity adds: Although the packaging may make some cereals - like granola and cereal clusters - appear healthy, they are often full of free sugars and unhealthy fat.

Some childrens cereals also have a lot of free sugar.

Instead, they not switch to porridge? Porridge oats or the instant variety are both fine - just avoid those with added free sugars like honey and golden syrup.

Wheat biscuits, shredded wheat or muesli (with no added sugar) are also great alternatives. For sweetness, add chopped fruit.

Read the rest here:
Type 2 diabetes: The food you should avoid eating for breakfast to lower blood sugar - Express

Santas Little Hackers Fulfills Christmas WishesMost toys dont work for children with disabilities, but a non-profit called Max Mods is changing that.

John Adsit Reflects On Anniversary Of Life-Changing CrashJohn Adsit knew his road to recovery wouldnt be easy, but five years after the accident that nearly killed him, its taken him down a path he didnt expect.

Geese Culling Likely To Continue In DenverThe city of Denver will likely continue with culling as part of its three year plan to manage the Canada Goose population in the metro area.

Cyclists Say Bike Lanes Are Snowpacked And Icy One Week After StormOne week after a storm dumped several inches of snow in Denver, the city's Public Works Department is working to clear icy residential roads.

Jimmy Buffet Brings Margaritaville To Denver Stage"Escape to Margartaville" opens Dec. 23 at the Buell Theatre.

Polar Bear Formally At Denver Zoo Is Now A FatherA polar bear that once called the Denver Zoo home is now a father.

Denver-Based Sleeping Giant To Help Boulder Beer CompanyBoulder Beer Company products will still be sold on the shelves in 2020 and beyond, despite the companys recent decision to downsize and stop nationwide distribution.

More Melting Before Next SnowWatch Dave Aguilera's Forecast

From Colorado To Africa, Bridge Of Life Provide Medical CareNewmont Goldcorp has joined with DaVita's Bridge of Life to provide medical care to the communities in Ghana.

Whooping Cough Reported At 5 Colorado Schools As Lawmakers Convene Vaccine SummitAn outbreak of whooping cough in Boulder has now spread to five schools. It comes as lawmakers convene a vaccine summit at the state capitol.

Colorado Snowboarder Among Ski.com Dream Job WinnersIt's a dream job for many-- getting paid to travel to some of the best ski resorts in the world and document their travels

New Murals Decorate Denver Streets Thanks To The Urban Arts FundDenver Arts and Venues is showing off eight new murals around Denver.

Driver Confuses Gas, Brake Pedal, Crashes Into StairsA woman mistook the gas pedal for the brake in her car and smashed into the stairs at a condominium complex in Arapahoe County Tuesday morning.

'It's On All Of Us': Denver Reviews Rising Deaths On RoadsDenver city leaders joined federal officials from different transportation agencies to highlight their partnership working together to improve the roads for those who travel by car or any other method.

Snowcat Rescues People, Dogs From Extreme Weather On U.S. 285Nearly two dozen people and three dogs were rescued after being stranded on U.S. 285 between Kenosha Pass and Fairplay.

16th Street Mall Project Given Green LightPlans to overhaul the 16th Street Mall in downtown Denver are moving forward.

Veteran Pleads For Return Of S&S Concrete Restoration TrailerOver the weekend, the trailer full of equipment for S&S Concrete Restoration was stolen. All of it, uninsured.

Denver Broncos Unveil Cleats Designed To Highlight CharitiesThe players got to see their specialty cleats for the first time Tuesday morning at UCHealth Training Center.

Laviska Shenault, Jr. Heading To NFL Draft: 'Extremely Excited & Grateful'Laviska Shenault Jr., one of the most dynamic players ever to play at the University of Colorado, is forgoing his senior year to enter the NFL draft.

Lifestyle Changes To Prevent Type 2 Diabetes Offered At YMCAThere is a program in the Denver metro area to prevent Type 2 diabetes that encourages a healthy lifestyle.

Vail Firefighter Returns To Work After He Was Struck By CarAn off-duty Vail firefighter who was hit by a car and seriously injured after stopping to help the victims of a multi-car crash on Interstate 70 in March has returned to work.

Governor, Santa Honor Colorado National Guard FamiliesThey deserve endless praise, but most will tell you, their families have the hardest jobs.

Denver's Residential Streets Sprayed With De-Icer To Clear RoadsDenver Public Works decided to send out a fleet of nearly 30 trucks to target residential streets with

Police Search For Abbas Abdal Kathem Abed In Connection With Woman's DeathSheridan Police are searching for a person of interest in connection with a death at a hotel. Chelsea Snider was found dead at an extended stay hotel in Sheridan on Sunday morning.

Here is the original post:
Lifestyle Changes To Prevent Type 2 Diabetes Offered At YMCA - CBS Denver

The Food and Drug Administration (FDA) has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged 6 years with diabetes mellitus. Previously, Toujeo was indicated for use in adults aged 18 years.

The approval was based on data from the phase 3, randomized, open-label, multicenter EDITION JUNIOR trial that compared the efficacy of Toujeo 300 Units/mL to Lantus (insulin glargine) 100 Units/mL in 463 patients aged 6 to 17 years with type 1 diabetes for at least 1 year. The primary end point was the change from baseline in HbA1c to Month 6. Results showed an adjusted mean change from baseline in HbA1c of -0.386% with Toujeo vs -0.404% with Lantus (adjusted mean difference: 0.018; 95% CI -0.159, 0.195).

With regard to safety, a similar percentage of patients in both groups experienced 1 event of severe and/or documented (70mg/dL) hypoglycemia (97% and 97.8% for Toujeo 300 Units/mL and Lantus 100 Units/mL, respectively). Numerically, the percentage of patients who experienced severe hypoglycemia or had 1 event of hyperglycemia with ketosis (ketones 1.5mmol/L) was lower with Toujeo compared with Lantus.

Toujeo, a long-acting human insulin analog, is available as 1.5mL SoloStar and 3mL Max SoloStar prefilled pens in 3-count packs.

For more information visit sanofi.com.

Go here to read the rest:
Toujeo Approved for Pediatric Patients With Diabetes - Monthly Prescribing Reference

BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. a medical technology company developing and aiming to commercialize the worlds first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis related diabetes (CFRD). Results of the study were published in the Journal of Cystic Fibrosis (J.S. Sherwood, R.Z. Jafri, C.A. Balliro, et al., Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study, Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2019.08.002).

Researchers at the Massachusetts General Hospital performed a three-arm, random-order, cross-over, pilot study comparing the bihormonal bionic pancreas versus the insulin-only bionic pancreas versus usual care for CFRD. The bionic pancreas dosing algorithms utilized in this pilot study were identical to those used in other studies in subjects with type 1 diabetes. There were no restrictions on activity and subjects continued their normal diet, exercise, and work throughout the study. The bionic pancreas was initialized only with subject body weight, without any information regarding their usual insulin regimen.

Given the sample size of the study, only descriptive statistics were reported for the group. The group mean blood-glucose level, as measured by continuous glucose monitoring (CGM), was nominally lower in both the bihormonal (139 15 mg/dl) and insulin-only (149 10 mg/dl) bionic pancreas study arms relative to the usual care study arm (159 35 mg/dl). During bionic pancreas arms, subjects used the meal announcement feature on average less than once per day, and survey data suggested that subjects had a decreased diabetes-management burden. Subjects reported they spent less time thinking about diabetes, felt more freedom with food choices, and had overall greater peace of mind.

We are encouraged by the results of this pilot study suggesting that our bionic pancreas technology can potentially be deployed in multiple conditions of glycemic disregulation, including CFRD, said Ed Damiano, President and Chief Executive Officer of Beta Bionics. We look forward to continuing our commitment to innovation through clinical research as we plan to test multiple applications of our technology in further clinical studies in an effort to maximize the potential good our technology and company can bring to the diabetes community.

This pilot study was supported by the National Institutes of Health under award number R01DK119699-01.

About Beta Bionics

Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong autonomous learning to automatically control glycemia. These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation whose founders in addition to Ed Damiano include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible. Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates.

Beta Bionics operates in Massachusetts and California. For further information, please visit http://www.betabionics.com or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.

Ed Damianoedamiano@betabionics.com

Ed Raskineraskin@betabionics.com

Investor Relations ContactJeremy Fefferjeremy@lifesciadvisors.com

See original here:
Encouraging Results of Pilot Study Testing Bionic Pancreas in Cystic Fibrosis-Related Diabetes Published in Journal of Cystic Fibrosis - GlobeNewswire

Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry.Why should you do so? Lets take a brief look at what statistics haveto say about hedge funds stock picking abilities to illustrate. The Standard and Poors 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge funds 20 preferred S&P 500 stocks generated a return of nearly 35% during the same period,withthe majority of these stock picks outperforming the broader market benchmark. Coincidence? It might happen to be so, but it is unlikely. Our research covering the last 18 years indicates that hedge funds' consensus stock picks generate superior risk-adjusted returns. That's why we believe it is wise to check hedge fund activity before you invest your time or your savings on a stock likeTandem Diabetes Care Inc (NASDAQ:TNDM).

Tandem Diabetes Care Inc (NASDAQ:TNDM) has seen an increase in hedge fund sentiment in recent months. Our calculations also showed that TNDM isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video below for Q2 rankings). Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

5 Most Popular Stocks Among Hedge Funds

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's flagship best performing hedge funds strategy returned 91% since May 2014 and outperformed the Russell 2000 ETFs by nearly 40 percentage points. Our short strategy outperformed the S&P 500 short ETFs by 20 percentage points annually (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

Samuel Isaly Orbimed Advisors

Unlike the largest US hedge funds that areconvinced Dow will soar past 40,000 or the world's most bearish hedge fundthat'smore convinced than ever that a crash is coming,our long-short investment strategy doesn't rely on bull or bear markets to deliver double digit returns. We only rely on the best performing hedge funds' buy/sell signals. Let's take a gander at the new hedge fund action regarding Tandem Diabetes Care Inc (NASDAQ:TNDM).

Heading into the fourth quarter of 2019, a total of 34 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 3% from the second quarter of 2019. On the other hand, there were a total of 22 hedge funds with a bullish position in TNDM a year ago. So, let's find out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

Story continues

No of Hedge Funds with TNDM Positions

Among these funds, Renaissance Technologies held the most valuable stake in Tandem Diabetes Care Inc (NASDAQ:TNDM), which was worth $76.3 million at the end of the third quarter. On the second spot was Redmile Group which amassed $68.4 million worth of shares. Consonance Capital Management, Columbus Circle Investors, and OrbiMed Advisors were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position Consonance Capital Management allocated the biggest weight to Tandem Diabetes Care Inc (NASDAQ:TNDM), around 5.97% of its portfolio. Sectoral Asset Management is also relatively very bullish on the stock, dishing out 4.4 percent of its 13F equity portfolio to TNDM.

With a general bullishness amongst the heavyweights, some big names have jumped into Tandem Diabetes Care Inc (NASDAQ:TNDM) headfirst. Consonance Capital Management, managed by Mitchell Blutt, initiated the most outsized position in Tandem Diabetes Care Inc (NASDAQ:TNDM). Consonance Capital Management had $60.3 million invested in the company at the end of the quarter. Peter S. Park's Park West Asset Management also made a $32.4 million investment in the stock during the quarter. The other funds with brand new TNDM positions are Jeffrey Jay and David Kroin's Great Point Partners, Chuck Royce's Royce & Associates, and John Osterweis's Osterweis Capital Management.

Let's go over hedge fund activity in other stocks similar to Tandem Diabetes Care Inc (NASDAQ:TNDM). These stocks are CarGurus, Inc. (NASDAQ:CARG), White Mountains Insurance Group Ltd (NYSE:WTM), Colfax Corporation (NYSE:CFX), and Macquarie Infrastructure Corporation (NYSE:MIC). This group of stocks' market caps are similar to TNDM's market cap.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position CARG,21,813076,1 WTM,16,185765,-1 CFX,30,652861,3 MIC,26,231644,-2 Average,23.25,470837,0.25 [/table]

View table hereif you experience formatting issues.

As you can see these stocks had an average of 23.25 hedge funds with bullish positions and the average amount invested in these stocks was $471 million. That figure was $587 million in TNDM's case. Colfax Corporation (NYSE:CFX) is the most popular stock in this table. On the other hand White Mountains Insurance Group Ltd (NYSE:WTM) is the least popular one with only 16 bullish hedge fund positions. Compared to these stocks Tandem Diabetes Care Inc (NASDAQ:TNDM) is more popular among hedge funds. Our calculations showed that top 20 most popular stocks among hedge funds returned 37.4% in 2019 through the end of November and outperformed the S&P 500 ETF (SPY) by 9.9 percentage points. Hedge funds were also right about betting on TNDM as the stock returned 17% during the first two months of Q4 and outperformed the market by an even larger margin. Hedge funds were clearly right about piling into this stock relative to other stocks with similar market capitalizations.

Disclosure: None. This article was originally published at Insider Monkey.

Related Content

More:
Hedge Funds Have Never Been This Bullish On Tandem Diabetes Care Inc (TNDM) - Yahoo Finance

360b / Shutterstock

The U.S. Food and Drug Administration (FDA) approved an expanded indication for Sanofis Toujeo (insulin glargine injection) for blood sugar control in adult and pediatric patients who are ages six years and older. This applies to both type 1 and 2 diabetes. Previously, Toujeo was approved only for adults aged 18 years and older.

The company announced the results of the EDITION JUNIOR clinical trial earlier in the month. It was the first randomized, controlled trial to compare Toujeo to Gla-100 in this patient population. The trial met its primary endpoint, demonstrating comparable decreases in average blood sugar over six months with both treatments and similar risk of low blood sugar events (hypoglycemia). In fact, the proportion of patients experiencing severe low blood sugar events and high blood sugar (hyperglycemia) with ketosis was numerically lower with Toujeo.

Based on the data, the European Medicines Agency (EMA)s Committee for Medicinal Products for Human Use recommended the expanded label in Europe.

Across the globe, between 50 and 80% of young people living with type 1 diabetes need more treatment options to help them achieve an average blood sugar level below 7.5%, said Dietmar Berger, Global Head of Development at Sanofi, at the time. By taking this step toward investigating an additional option for children and adolescents living with diabetes, we hope to provide another treatment for them and their physicians, to develop an individualized treatment plan that helps patients better manage their disease.

The EDITION JUNIOR study compared Toujeo to Gla-100 in 463 children and adolescents aged six to 17 years who had type 1 diabetes. They were evaluated for at least one year. They had HbA1C levels between 7.5% and 11.0% at the time of screening. The patients continued to use their existing mealtime insulin throughout the study.

The primary endpoint was non-inferior reduction of HbA1C after 26 weeks.

Insulin glargine injection is a long-acting, manufactured insulin. The injection holds three times as much insulin in 1ml as a standard 100 units/ml insulin.

Toujeo was originally approved for adults by the FDA in February 2015. Its primary competition is Novo Nordisks ultra-long-acting degludec, marketed as Tresiba. Both Toujeo and Tresiba are dosed once daily. The original insulin glargine is marketed by Sanofi as Lantus. It is facing competition from Boehringer Ingelheims Basaglar, the first insulin glargine follow-on approved by the FDA. It launched in 2016 after a patent battle with Sanofi.

In 2018, Toujeo brought in $840 million, while its Lantus sales dropped from $4.63 billion to $3.57 billion. Novo Nordisks Tresiba brought in $1.22 billion in 2018.

We know that living with type 1 diabetes means dealing with highs and lows in blood sugar, which are worrying and present substantial challenges for young people, said Thomas Danne, director of the Department of General Pediatrics and Endocrinology/Diabetology at the Childrens Hospital on the Bult, Hannover Medical School, Germany. In addition to the trial demonstrating safety and efficacy, the percentage of patients with severe hypoglycemia, and the percentage with hyperglycemia with ketosis, were numerically lower with Toujeo.

More:
FDA Approves Sanofi's Toujeo to Treat Childhood Type 1 and 2 Diabetes - BioSpace

A review of the literature demonstrates the value of the diabetes specialist nursing role for people with diabetes in hospital

There is a profound mismatch between the capacity of the diabetes specialist nurse (DSN) workforce and the steadily rising demand for diabetes services in the UK. A literature review of evidence in the field highlights the reasons for this, and the necessity to protect and propagate the DSN workforce.

Citation: Lawler J (2020) The role of specialist nurses for people with diabetes in hospital. Nursing Times [online]; 116: 1, 18-19.

Author: Jessica Lawler is research associate, London South Bank University.

An estimated one in six hospital beds are occupied by people with diabetes (NHS Digital, 2018), costing the NHS around 10bn a year (Diabetes UK, 2014). However, the number of diabetes inpatient specialist nurses in post is significantly lower than the recommended one per 250 beds (NHS Digital, 2017). In total, 22% of hospitals have no diabetes specialist nurses (DSNs) at all and only 12% provide a seven-day service (NHS Digital, 2019).

Lack of title protection or a national accreditation framework for DSNs, means there is wide variation in credentialing and role structure. This can reduce the potential for peer support and means specialist nurses from different trusts have varying expectations, training and experience. NHS Englands (2019) NHS Long Term Plan specifies that all hospitals should provide a DSN service to reduce variations in care. A literature review of evidence on the DSN workforce has clarified the ways they improve patient outcomes and experiences (Lawler et al, 2019); this article summarises its findings.

Caring for people with diabetes in hospital requires expertise in treatment and an understanding of how diabetes may affect care (NHS Digital, 2019). NHS England (2016) states the benefits of DSN interventions include reducing inpatient harm, including prescription errors and medication errors. In 2017, 31% of inpatients with diabetes experienced at least one diabetes-related medication error (NHS Digital, 2017). Furthermore, hospital-acquired emergency states, such as diabetic ketoacidosis and hyperglycaemia, are potentially fatal, yet preventable. In 2017, 28% of inpatients with diabetes did not see a specialist diabetes team when they should have (Diabetes UK, 2018).

DSNs respond to crises, prevent patient deterioration, and provide safe and consistent care. In addition, specialist nurses are widely acknowledged to reduce unscheduled care (Read, 2015). Reasons (2000) Swiss Cheese model showed safety is more than just the absence of harm; specialist nurses ensure the delivery of safe care, rather than simply reducing errors.

As well as reducing inpatient harm, DSNs:

Reduced length of stay is an often-used metric to determine the effectiveness or value of DSNs (NHS England, 2019). However, it should not be the only target or measure of quality or effectiveness and it is not an accurate or representative guide of safe care. Other factors to consider are:

The wide-reaching benefits of specialist nurses are well documented but narrowly measured (Leary, 2011).

Working in partnership with people who have diabetes to promote self-management is an invaluable part of educative interventions by DSNs. Improving their understanding of the physical, social and emotional effects of the condition, along with the tools to manage and cope with these effects, is part of comprehensive care. Providing psychological care for patients, and support and advice for families and carers, is also crucial.

As Lawler et al (2019) elucidate, education by DSNs is usually given in one-to-one therapeutic conversations, and associated with improved outcomes. There is a long-standing debate around the effectiveness and suitability of providing bedside education in hospital, but the review suggests disempowerment is common in people with the condition in hospital, and that diabetes education is critical for those with newly diagnosed diabetes to reduce avoidable hospital admissions.

DSNs also provide continuity of care for people with diabetes when they are in hospital whether for diabetes-related issues or other conditions giving essential care and managing complex needs and care planning. This undoubtedly improves the patient experience and quality of care.

With the wealth of evidence showing their value, why are there significantly fewer DSNs than recommended and how can this be remedied? The specialist nursing workforce is continuously asked to prove its worth, with nurses having to fight to remain in post or for posts to be created. Simplistic perceptions and short-term cost considerations often prevent consideration of the benefits and necessity of specialist nurses, and long-term financial and economic benefits are often ignored (Read, 2015).

Workforce pressures, and a shortfall in specialist nurses, mean the task of training new DSNs falls on teams already struggling with their workload. Yet moving from crisis management to proactive care relies on having a well-staffed and stable workforce. The review calls for accreditation and protection of specialist nursing titles, along with increased inpatient DSN roles to meet, if not surpass, national targets.

Appropriate and effective use of DSNs for inpatients is important in ensuring high standards of care. The NHS Institute for Innovation and Improvement launched its ThinkGlucose campaign in 2009 with the aim of improving the care, outcomes and experience of people with diabetes in hospital. The campaign, which used a traffic-light system to advise staff which patients should be referred to specialist diabetes teams, reduced inappropriate referrals, and increased diabetes knowledge and awareness among other hospital staff (Eaglesfield, 2012). Although the tool was created to improve the efficiency of DSNs work, the way it is used in practice is not explicitly recorded or defined. Further reporting using such tools could help demonstrate the benefits of DSNs.

Increasing the accessibility and convenience of care is important and telemedicine is now viewed as a way to provide guidance to patients about next steps or when to seek advice from a health professional. It involves specialist assessment and active listening to meet patients information needs and educate them on symptom control, and is particularly well received for people with long-term conditions.

Diabetes care should be patient centred and tailored to the individual to promote confidence in self-management. The review concluded that telemedicine was a cost-effective way for DSNs to deliver care. As well as enabling follow-up for some recently discharged patients without them needing to visit a clinic or make an appointment, it purportedly reduces the number of acute hospital admissions. DSNs ran telephone helplines, as well as holding telephone appointments or check-ins, to support rather than substitute direct contact care.

DSNs reportedly have limited access to, and time for, professional development. This could threaten the future of the role by creating problems with recruitment and retention. There is no census of DSNs in the UK and, therefore, no way of accurately predicting future workforce needs. Currently one in 15 people in the UK have diabetes and this proportion is predicted to rise (NHS Digital, 2018). An annual national census of the diabetes workforce would enable the NHS to plan for a sustainable and efficient workforce capable of meeting the demands of an increasing diabetes workload. Although undertaking the census might add to current workload pressures, short-term action may be needed for long-term success.

The review shows DSNs improve care and outcomes for people with diabetes by:

There is a profound mismatch between the limited capacity of the DSN workforce and the steadily rising demand for diabetes services in the UK. The results of Lawler et als (2019) literature review highlight the necessity to protect and propagate the DSN workforce.

Diabetes UK (2018) Making Hospitals Safe for People With Diabetes.

Diabetes UK (2014) The Cost of Diabetes: Report.

Eaglesfield B (2012) ThinkGlucose at an acute hospital a roller-coaster project. Journal of Diabetes Nursing; 16: 9, 356-362.

Lawler J et al (2019) Does the diabetes specialist nursing workforce impact the experiences and outcomes of people with diabetes? A hermeneutic review of the evidence. Human Resources for Health; 17: 65.

Leary A (2011) How nurse specialists can demonstrate their worth. Gastrointestinal Nursing; 9: 6, 46-49.

NHS Digital (2019) National Diabetes Inpatient Audit: Hospital Characteristics, 2018: England and Wales.

NHS Digital (2018) National Diabetes Inpatient Audit: England and Wales, 2017.

NHS Digital (2017) National Diabetes Inpatient Audit (NaDIA): 2016.

NHS England (2019) The NHS Long Term Plan.

NHS England (2016) National Diabetes Treatment and Care Programme: Introduction to and Supporting Documentation for Value Based Transformation Funding Site Selection.

Read C (2015) How specialists can help you. In: Time for Some Advanced Thinking? The Benefits of Specialist Nurses.

Reason J (2000) Human error: models and management. BMJ; 320: 768.

See the original post here:
The role of specialist nurses for people with diabetes in hospital - Nursing Times

Funding was awarded to Bluedrop Medical, Innerstrength, Cadscan, Jinga Life and Infocare to develop new innovations that address complications caused by diabetes.

Enterprise Ireland and the Health Service Executive (HSE) have awarded 100,000 in funding to five companies tackling health complications that arise as a result of diabetes. The funding was awarded through Enterprise Irelands Small Business Innovation Research (SBIR) programme.

The investment will enable the five SMEs to develop new innovations and technologies to address complications related to diabetes. The specific areas of diabetes that these businesses focus on include reducing the risk of women developing type 2 diabetes following gestational diabetes, and screening for diabetic foot disease.

The Enterprise Ireland and HSE SBIR collaboration was announced in December 2018, with the two organisations coming together with the joint goal of delivering improved patient care through the intelligent use of technology.

The successful businesses include Galways Bluedrop Medical, which is a start-up that has developed a home-based, remote monitoring screening device for early identification and prevention of diabetic foot ulcers.

UK company Cadscan will also receive funding for its low-cost foot screening tool that can quickly determine a patients risk of ulceration.

The other recipients include Innerstrength, which has a platform and multi-disciplinary approach to reducing the risk of type 2 diabetes in women after pregnancy, as well as Infocare, which has developed technology that connects to medical devices to allow point-of-care and at-home testing to be reliably uploaded to a patients medical record.

The final firm is Jinga Life, a Dublin-based business that has created a mobile digital health platform to enable users to manage their familys health information, medical appointments and clinical images.

Julie Sinnamon, chief executive of Enterprise Ireland, commented: Enterprise Ireland is delighted to partner with the HSE on SBIRs first health challenge. We see huge potential for the Irish healthcare system to leverage SBIR to deliver more efficient and more fit for purpose technologies.

Congratulations to the phase-one winners and we look forward to the progression of their emerging technologies. These companies now have a valuable opportunity to co-design innovative solutions with Irish clinicians to tackle diabetes, which they can then commercialise and ultimately sell globally.

Fran Thompson, acting CIO at the HSE, said: Huge congratulations to the five shortlisted firms. We were very impressed with the submissions received and are very happy to partner with Enterprise Ireland on this initiative.

The burden of chronic disease is a huge one across ageing western populations, including the Irish population, with diabetes a key area of concern. We see this innovative deployment of technology as a key tool in delivering care closer to home, putting the individual at the centre of the design process, and delivering real benefits for the health service, the firms involved and most importantly, the diabetes patient.

Read the original here:
EI and the HSE award five firms funding to address challenges related to diabetes - Siliconrepublic.com